FDA approves Jakafi to treat patients with a chronic type of bone marrow disease

Share this content:
FDA approves Jakafi to treat patients with a chronic type of bone marrow disease
FDA approves Jakafi to treat patients with a chronic type of bone marrow disease
FDA approves Jakafi to treat patients with a chronic type of bone marrow disease First FDA-approved drug for polycythemia vera For Immediate Release December 4, 2014 Release The U.S. Jakafi is the first drug approved by the FDA for this condition. Polycythemia vera occurs when too many red blood cells are made in the bone marrow.
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters